Posted by Michael Wonder on 19 Sep 2016
Agenda for 21 September 2016 TC meeting
19 September 2016 - The Transparency Commission will consider the reimbursement of a number of new medicines and blood products.
The Commission will consider the reimbursemenet of:
- Nivolumab (Opdivo)
- Travoprost (Travatan)
- Albutrepenonacog alfa (Idelvion)
- Eftrenonacog alfa (Alprolix)
- Ticagrelor (Brilique)
- Paliperidone palmitate (Trevicta)
